Evidence map›Paper›PMID 38926247›Full record

ReviewScience China. Life sciences2024

Suppressor tRNA in gene therapy.

Jingjing Ruan, Xiaoxiao Yu, Huixia Xu, Wenrui Cui, Kaiye Zhang, Chenyang Liu, Wenlong Sun, Xiaodan Huang, Lei An, Yue Zhang

Abstract readReview
PubMed Publisher
In one paragraph

Review in Science China. Life sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. [Abnormal transfer RNA epigenetic modifications and related impact on neurodegenerative diseases].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jingjing RuanThe Children's Hospital, National Clinical Research Center for Child Health, Zhejiang University School of Medicine, Liangzhu Laboratory, Hangzhou, 310000, China.
Xiaoxiao YuLiangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, 311121, China.
Huixia XuDepartment of Thoracic and Cardiovascular Surgery, Huaihe Hospital of Henan University, Henan University, Kaifeng, 475000, China.
Wenrui CuiTranslational Medicine Center, Huaihe Hospital of Henan University, Henan University, Kaifeng, 475000, China.
Kaiye ZhangEye Center, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310009, China.
Chenyang LiuTranslational Medicine Center, Huaihe Hospital of Henan University, Henan University, Kaifeng, 475000, China.
Wenlong SunLiangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, 311121, China.
Xiaodan HuangEye Center, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310009, China.
Lei AnTranslational Medicine Center, Huaihe Hospital of Henan University, Henan University, Kaifeng, 475000, China. anlei@henu.edu.cn.
Yue ZhangThe Children's Hospital, National Clinical Research Center for Child Health, Zhejiang University School of Medicine, Liangzhu Laboratory, Hangzhou, 310000, China. yue.zhang@zju.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Suppressor tRNAs are engineered or naturally occurring transfer RNA molecules that have shown promise in gene therapy for diseases caused by nonsense mutations, which result in premature termination codons (PTCs) in coding sequence, leading to truncated, often nonfunctional proteins. Suppressor tRNAs can recognize and pair with these PTCs, allowing the ribosome to continue translation and produce a full-length protein. This review introduces the mechanism and development of suppressor tRNAs, compares suppressor tRNAs with other readthrough therapies, discusses their potential for clinical therapy, limitations, and obstacles. We also summarize the applications of suppressor tRNAs in both in vitro and in vivo, offering new insights into the research and treatment of nonsense mutation diseases.

Indexed as

Codon, NonsenseGenetic TherapyRNA, TransferAnimalsHumansProtein BiosynthesisCodon, NonsenseRNA, Transfergene therapynonsense mutationPTCreadthroughsuppressor tRNA

Identifiers

PMID38926247

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.